Other

University of Washington

Thalia Papayannopoulou

George Stamatoyannopoulos

André Lieber

Denise R Farrer

Dmitry M Shayakhmetov

The invention relates to in vivo peripheralization of CD34cells by administering anti-VLA-4 antibodies or anti-VCAM-1 antibodies.

Peripheralization of hematopoietic stem cells

The present invention provides for novel chimeric Ad-vectors carrying transgene, or portions of transgenes for stable and efficient gene transfer into diverse cell types or tissues in a CAR- and/or &#x3b1;&#x3b2;-independent manner. Also provided are methods for producing such vectors and the use thereof for gene therapy to target a specific cell type or tissue.

Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration

The invention is directed to fetal globin inducing factor (FGIF), and to nucleic acids encoding FGIF. FGIF controls the expression of fetal globin gene products. An FGIF polypeptide is shown in FIG.,and nucleotide sequences that encode FGIF polypeptides are shown in FIGS.,and,. The invention is also directed to therapeutic methods employing FGIF polypeptides, encoding nucleic acids and functional fragments thereof for the treatment of globin disorders and to methods for screening compounds that modulate fetal globin gene expression as well as compounds identified by these methods.

Fetal globin inducing factor

The invention provides methods for peripheralizing CD34.sup.+ cells, including hematopoietic stem cells. In a first aspect, the method comprises the step of administering a blocking agent of VLA-4 antigen on the surface of CD34.sup.+ cells. In a second aspect, the method comprises administering a blocking agent of VLA-4 antigen on the surface of CD34.sup.+ cells and administering a stimulating agent of CD34.sup.+ cell proliferation in vivo. The method according to the invention is useful in the treatment of cancer or AIDS, and in gene therapy.

The invention provides methods for peripheralizing CD 34.sup.+ cells, including hematopoietic stem cells. In a first aspect, the method comprises the step of administering a blocking agent of VLA-4 antigen on the surface of CD34.sup.+ cells. In a second aspect, the method comprises administering a blocking agent of VLA-4 antigen on the surface of CD34.sup.+ cells and administering a stimulating agent of CD34.sup.+ cell proliferation in vivo. The method according to the invention is useful in the treatment of cancer or AIDS, and in gene therapy.

Growing community of inventors

Seattle, WA, United States of America

Thalia Papayannopoulou